Nicotinic acid

ApprovedSmall molecule

Sanofi

Nicotinic acid is one of 260 small molecule programs targeting Liver Transplant. It is currently in Approved.

Indications

Total Trials

Active Trials

259

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Familial HypercholesterolemiaActive, not recruiting

AtherosclerosisActive, not recruiting

Retinal Vein OcclusionActive, not recruiting

MigraineActive, not recruiting

Peripheral Artery DiseaseActive, not recruiting

Type 2 DiabetesActive, not recruiting

Heart DiseaseActive, not recruiting

Homozygous Familial HypercholesterolemiaActive, not recruiting

Liver TransplantPhase 2

Active, not recruiting

Familial HypercholesterolemiaPhase 2

Active, not recruiting

AtherosclerosisPreclinical

Active, not recruiting

Retinal Vein OcclusionPhase 2/Phase 3

Active, not recruiting

MigrainePhase 2

Active, not recruiting

Peripheral Artery DiseaseApproved

Active, not recruiting

Type 2 DiabetesPreclinical

Active, not recruiting

Heart DiseaseApproved

Active, not recruiting

Homozygous Familial HypercholesterolemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Nicotinic acid

Sanofi

Approved

3 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Glargine

Eli Lilly

Preclinical

8 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 8

Aurlumyn

BBTG International Inc.

Preclinical

1 9

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 10

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Study completion

NCT03540758

Q2 2028

N/ARecruiting

Bariatric Surgery

NCT05934409

Clinical

Trials by Indication[1]

Type 2 Diabetes3 trials

Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)

Completed·UUniversité de Sherbrooke·N/A·NCT02808182·50 enrolled

Brown Adipose Tissue Metabolism in Type 2 Diabetes

Completed·UUniversité de Sherbrooke·N/A·NCT05092945·6 enrolled

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Completed· Sanofi logo

Sanofi·Phase 4·NCT02642159·413 enrolled

Retinal Vein Occlusion2 trials

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

Completed·PPalo Alto Medical Foundation·Phase 2/3·NCT00493064·63 enrolled

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

Terminated·PPalo Alto Medical Foundation·Phase 2/3·NCT00500045·36 enrolled

Familial Hypercholesterolemia2 trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Completed· Sanofi logo

Sanofi·Phase 3·NCT03510884·153 enrolled

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Completed· Sanofi logo

Sanofi·Phase 2·NCT02890992·42 enrolled

Liver Transplant1 trial

The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients

Withdrawn·—·Phase 2·NCT03685773

Bariatric Surgery1 trial

Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery

Recruiting·UUniversité de Sherbrooke·N/A·NCT05934409·40 enrolled

12 more indications

Peripheral Artery Disease1 trial

Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)

Unknown status·MMedical University of Vienna·Phase 4·NCT00712049·200 enrolled

Inflammation1 trial

Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects

Completed·UUniversity Hospital, Toulouse·Phase 2·NCT01083329·24 enrolled

Heart Disease1 trial

Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL

Terminated·XXavier Pinto Sala·Phase 4·NCT01450410·12 enrolled

Humans1 trial

Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10)

Completed·UUniversité de Sherbrooke·N/A·NCT05553184·12 enrolled

Lip1 trial

Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)

Unknown status·—·Phase 3·NCT00633698·150 enrolled

Migraine1 trial

Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine

Completed·—·Phase 2·NCT05846373·58 enrolled

Atherosclerosis1 trial

Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid

Terminated·—·N/A·NCT01159054·22 enrolled

PreDiabetes1 trial

Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes

Completed·UUniversity Hospital Schleswig-Holstein·Phase 1·NCT06378125·60 enrolled

Homozygous Familial Hypercholesterolemia1 trial

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Completed· Sanofi logo

Sanofi·Phase 3·NCT03510715·18 enrolled

Tics1 trial

Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression

Unknown status·HHeidelberg University·Phase 1·NCT00176020·18 enrolled

Statin1 trial

The Low HDL On Six Weeks Statin Therapy (LOW) Study

Unknown status·—·Phase 4·NCT00238004·60 enrolled

Unspecified1 trial

Regulation of Endogenous Glucose Production by Central KATP Channels

Recruiting·MMeredith Hawkins·Phase 2·NCT03540758·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Nicotinic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nicotinic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nicotinic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Nicotinic acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Trials by Indication[1]

Type 2 Diabetes3 trials

Retinal Vein Occlusion2 trials

Familial Hypercholesterolemia2 trials

Liver Transplant1 trial

Bariatric Surgery1 trial

Peripheral Artery Disease1 trial

Inflammation1 trial

Heart Disease1 trial

Humans1 trial

Lip1 trial

Migraine1 trial

Atherosclerosis1 trial

PreDiabetes1 trial

Homozygous Familial Hypercholesterolemia1 trial

Tics1 trial

Statin1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News